Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Suheung Co., Ltd. (008490.KS)
KRW21,350.00
+600.00 (+2.89%)
KR KSC Healthcare Drug Manufacturers - Specialty & Generic
Address
Jung-An Building 130-845
Seoul, KR
Seoul, KR
CEO
Joohwan Yang
Website
suheung.com
IPO
2000-01-04
ISIN KR7008490005
Description
Suheung Co., Ltd. specializes in the production and provision of empty hard capsules, which are primarily utilized within the pharmaceutical and nutraceutical industries. The company further diversifies its business by offering comprehensive contract manufacturing services, accommodating a wide array of dosage types and packaging arrangements. Additionally, Suheung provides original equipment manufacturing (OEM) for paintball products. This South Korean firm, headquartered in Seoul, began its operations in 1973.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
KRW21,350.00
+600.00 (+2.89%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
46.7K
Beta
0.46
Float Shares
5.25M
Free Float %
47.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +10.86% | +12.62% | +18.39% | -10.04% | -8.54% | +2.09% | +35.75% | -23.78% | -62.41% | -53.89% | +245.67% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
21,350.00
DCF (Unlevered)
15,257.60
-28.5%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
| Rating | 2025-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
1.35
Distress
Piotroski F-Score
7 / 9
Strong
MOAT Score
4 / 10
Developing
Composite Rating
B+
Overall Score
3 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
4 / 5
High
ROA Score
4 / 5
High
D/E Score
1 / 5
Low
P/E Score
3 / 5
Medium
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+10.6% ★ Q1'26: +11.5% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+138.0% ★ Q1'26: +99.0% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+3.8% Q1'26: +3.7% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+7.0% Q1'26: +10.5% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+4.9% Q1'26: +6.6% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+4.1% Q1'26: +0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×4.77× Q1'26: 3.53× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
304.12B
est: 305.80B (-0.5%)
|
340.36B
est: 305.80B (+11.3%)
|
350.01B
est: 328.70B (+6.5%)
|
393.48B
est: 362.50B (+8.5%)
|
460.73B
est: 457.25B (+0.8%)
|
553.01B
est: 570.95B (-3.1%)
|
596.73B
est: 591.90B (+0.8%)
|
634.97B
est: 662.60B (-4.2%)
|
594.57B
est: 594.60B (0.0%)
|
653.26B
est: 649.90B (+0.5%)
|
722.31B
est: 694.60B (+4.0%)
|
725.80B
725.80B – 725.80B
+4.5% YoY
|
750.20B
750.20B – 750.20B
+3.4% YoY
|
| EBITDA |
53.62B
est: 48.28B (+11.0%)
|
61.47B
est: 48.28B (+27.3%)
|
62.66B
est: 51.90B (+20.7%)
|
69.71B
est: 57.24B (+21.8%)
|
80.14B
est: 72.20B (+11.0%)
|
110.40B
est: 90.15B (+22.5%)
|
114.89B
est: 93.46B (+22.9%)
|
98.61B
est: 104.62B (-5.7%)
|
77.03B
est: 93.88B (-18.0%)
|
73.47B
est: 93.08B (-21.1%)
|
91.23B
est: 99.49B (-8.3%)
|
103.95B
103.95B – 103.95B
+4.5% YoY
|
107.45B
107.45B – 107.45B
+3.4% YoY
|
| EBIT |
33.62B
est: 29.72B (+13.1%)
|
39.44B
est: 29.72B (+32.7%)
|
37.66B
est: 31.95B (+17.9%)
|
43.05B
est: 35.23B (+22.2%)
|
50.42B
est: 44.44B (+13.5%)
|
76.17B
est: 55.49B (+37.3%)
|
76.82B
est: 57.52B (+33.6%)
|
63.19B
est: 64.40B (-1.9%)
|
40.72B
est: 57.79B (-29.5%)
|
33.61B
est: 54.38B (-38.2%)
|
50.70B
est: 58.12B (-12.8%)
|
60.73B
60.73B – 60.73B
+4.5% YoY
|
62.77B
62.77B – 62.77B
+3.4% YoY
|
| Net Income |
22.84B
est: 28.40B (-19.6%)
|
27.31B
est: 28.40B (-3.8%)
|
23.08B
est: 37.22B (-38.0%)
|
25.74B
est: 44.72B (-42.5%)
|
31.72B
est: 35.89B (-11.6%)
|
53.00B
est: 49.20B (+7.7%)
|
53.69B
est: 48.90B (+9.8%)
|
33.98B
est: 47.96B (-29.1%)
|
6.12B
est: 7.41B (-17.4%)
|
18.28B
est: 19.57B (-6.6%)
|
43.49B
est: 20.26B (+114.7%)
|
22.62B
22.62B – 22.62B
+11.7% YoY
|
25.32B
25.32B – 25.32B
+12.0% YoY
|
| SGA |
14.00B
est: 14.42B (-2.9%)
|
14.82B
est: 14.42B (+2.8%)
|
16.40B
est: 15.50B (+5.8%)
|
14.80B
est: 17.09B (-13.4%)
|
19.20B
est: 21.56B (-10.9%)
|
19.61B
est: 26.92B (-27.1%)
|
29.54B
est: 27.91B (+5.9%)
|
41.50B
est: 31.24B (+32.8%)
|
26.24B
est: 28.04B (-6.4%)
|
26.96B
est: 32.49B (-17.0%)
|
35.89B
est: 34.73B (+3.4%)
|
36.29B
36.29B – 36.29B
+4.5% YoY
|
37.51B
37.51B – 37.51B
+3.4% YoY
|
| EPS |
1,974.00
est: 2,554.00 (-22.7%)
|
2,360.00
est: 2,554.00 (-7.6%)
|
1,995.00
est: 3,347.00 (-40.4%)
|
2,303.00
est: 4,022.00 (-42.7%)
|
2,852.67
est: 3,228.00 (-11.6%)
|
4,766.49
est: 4,424.50 (+7.7%)
|
4,828.54
est: 4,398.00 (+9.8%)
|
3,056.41
est: 4,313.00 (-29.1%)
|
550.00
est: 666.00 (-17.4%)
|
1,643.12
est: 1,692.00 (-2.9%)
|
3,910.89
est: 1,751.00 (+123.4%)
|
1,955.00
1,955.00 – 1,955.00
+11.7% YoY
|
2,189.00
2,189.00 – 2,189.00
+12.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | B+ | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-12 | B+ | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-11 | B+ | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-08 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-05-07 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-05-06 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-05-04 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-30 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-29 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-28 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-27 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-24 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-23 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-22 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-21 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-20 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-17 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-16 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
83.53B
OE per share TTM
7,677.58
Owner's Yield
51.87%
Maintenance CapEx ratio
91.36%
Maint CapEx / Avg PPE
72.8%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 5 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Kodex KOSPI 226490.KS | 0.01% | 48.6K | 0.15% |
| 2 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 119.8K | 0.39% |
| 3 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 58.4K | 0.29% |
| 4 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 29.2K | 0.28% |
| 5 | Dimensional - Emerging Markets ex China Core Equity ETF DEXC | 0.00% | 309.54 | 0.56% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
68.88M
Shares Outstanding
11.12M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Joohwan Yang | Chairperson and Chief Executive Officer | — | male |
| Sung-Geol Yoon | President | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 008490.KS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
